• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, July 17

The Mumbai-based Glenmark Pharmaceutical Ltd's wholly owned subsidiary in the UK has entered into an agreement with Generics UK, a unit of Germany's Merck KgaA, for eight dermatological products.

The deal between Glenmark Pharmaceutical [UK] Ltd and Generics is for the joint-development, filing and marketing of eight generic dermatological products for the European market. The products have annual sales of $225 million in the region, a note from Glenmark said.

The company had started its commercial operations in Europe through Glenmark Pharmaceuticals [UK] Ltd, set up in 2004. While both Glenmark and Merck would be responsible for their own sales and marketing, Glenmark will develop, manufacture and supply the products. The first of these products has been filed and is slated for launch in 2007, the note said. The remaining products are likely to be launched by 2010. Glenmark shares were down marginally at Rs 313.95 on the BSE.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ICI board to consider share buyback

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line